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Background: Patients with single ventricle physiology typically undergo multiple surgical palliations culminating in the Fontan operation. The 
efficient function of the Fontan is dependent on numerous factors, including the presence of a low pulmonary vascular resistance. Phosphodiesterase 
5 inhibitors have recently been shown to improve cardiac output and functional capacity by lowering vascular resistance. We sought to test the 
efficacy and safety of endothelin blockade with Bosentan in a cohort of adult patients with Fontan physiology.
methods: Seven adult Fontan patients completed this single center open label clinical trial. Patients were treated with Bosentan for 4 months. 
Cardiac MRI, six minute walking distance (6MWD), brain natriuretic peptide (BNP), and NYHA functional class were compared before and after 
treatment using paired T-test.
results: 6MWD improved by 73 meters, from a mean of 435 meters (SD=92, SE 35) to 508 meters (SD=93, SE=35) (p=0.03). MRI resting aortic 
flow increased from 3.3 l/min (SD=1.27, SE=0.73) to 4.4 l/min (SD=0.9, SE=0.54) (p=0.03). NYHA class improved in 3 patients and worsened in 1 
patient. BNP, AST, and ALT did not change significantly. Of three patients with elevated baseline bilirubin, 2 had normalized at the completion of the 
study, the other was unchanged. Mean duration of therapy was 4.1 ± 0.51 months. There were no deaths or hospitalizations. Two adverse advents 
occurred. One patient complained of fatigue and chest pain after 87 days and withdrew from the study. After extensive work-up, it was determined 
that her symptoms were not related to treatment. The second patient suffered palpitations and fatigue after 75 days of treatment, no concerning 
arrhythmias were identified but symptoms improved with increased antiarrhythmic dose.
conclusions: In this cohort of adult patients with Fontan physiology, endothelin blockade with Bosentan resulted in improved 6MWD and MRI 
derived resting cardiac output, suggesting a positive effect on pulmonary vascular resistance. Bosentan was well tolerated and there were no adverse 
events requiring hospitalization. Hepatic function was not adversely affected despite elevations in baseline Bilirubin in three patients.
